Page last updated: 2024-11-12
ventiloquinone l
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
ventiloquinone L: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 11415004 |
| CHEMBL ID | 594257 |
| MeSH ID | M0486300 |
Synonyms (6)
| Synonym |
|---|
| rnggdqgpilktqu-jgvffnpusa- |
| inchi=1/c16h16o5/c1-7-4-10-13(8(2)21-7)16(19)14-11(15(10)18)5-9(20-3)6-12(14)17/h5-8,17h,4h2,1-3h3/t7-,8+/m0/s1 |
| CHEMBL594257 |
| (+)-ventiloquinone |
| ventiloquinone l |
| (1r,3s)-9-hydroxy-7-methoxy-1,3-dimethyl-3,4-dihydro-1h-benzo[g]isochromene-5,10-dione |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (5)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID453796 | Inhibition of Xanthomonas vasicola XhoI assessed as pBSKS cleavage at 100 uM by endonuclease assay | 2009 | Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20 | Pyranonaphthoquinone derivatives of eleutherin, ventiloquinone L, thysanone and nanaomycin A possessing a diverse topoisomerase II inhibition and cytotoxicity spectrum. |
| AID453793 | Inhibition of human topoisomerase 2alpha-mediated kinetoplast DNA decatenation at 100 uM | 2009 | Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20 | Pyranonaphthoquinone derivatives of eleutherin, ventiloquinone L, thysanone and nanaomycin A possessing a diverse topoisomerase II inhibition and cytotoxicity spectrum. |
| AID453795 | Induction of DNA intercalation in pRYG DNA at 100 uM by agarose gel electrophoresis | 2009 | Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20 | Pyranonaphthoquinone derivatives of eleutherin, ventiloquinone L, thysanone and nanaomycin A possessing a diverse topoisomerase II inhibition and cytotoxicity spectrum. |
| AID453794 | Inhibition of human topoisomerase 2alpha-mediated relaxation of double-stranded pRYG DNA at 100 uM by agarose gel electrophoresis | 2009 | Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20 | Pyranonaphthoquinone derivatives of eleutherin, ventiloquinone L, thysanone and nanaomycin A possessing a diverse topoisomerase II inhibition and cytotoxicity spectrum. |
| AID453797 | Growth inhibition of Saccharomyces cerevisiae BY4741 after 24 hrs | 2009 | Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20 | Pyranonaphthoquinone derivatives of eleutherin, ventiloquinone L, thysanone and nanaomycin A possessing a diverse topoisomerase II inhibition and cytotoxicity spectrum. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.50
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||